About Us
Curaxys is a biotechnology company that researches, develops, produces and marketing biosimilars products using new biotechnology process and offering to the market, high quality product biosimilars at reasonable prices for the diseases treatment.
Technologies:
It is remarkable to inform that in the last 20 years have demonstrated that the baculoviruses maintains a reputation for producing high yields of recombinant proteins in insect cells. Despite the difficulties of working with a virus in eukaryotic cells, the fact that posttranslational modifications such as glycosylation, fatty acid acylacion , disulfide bond formation, and phosphorylation are carried out very similar to the same process in mammalian cells, demonstrating the value of bacuviruses as expression vectors for biosimilars productions
What we offer:
We offer a complete range of biopharmaceuticals biosimilars with structure, recombinant protein and monoclonal antibody.
The products are focused to improve the quality of life of patient with new concept of product at reasonable cost in the field of the immunology, cancer treatment, multiple sclerosis, and virology.
The WHO
forecast
is that
globally, there were an estimated 12.4 million incident cases of cancer in
2008 (6 672 000 in men and 5 779 000 in women) and 7.6 million deaths from
cancer (4 293 000 in men and 3 300 000 in women). Over
half
of the incident cases occurred in residents of four WHO regions with a large
proportion of countries
of low- and middle-income—AFRO, EMRO, SEARO and WPRO . Globally, lung cancer
was the commonest incident cancer and cause of cancer-related mortality in
men; in women, the most common incident cancer and cause of cancer-related
death was breast cancer
The cost of biologic medicines can be tremendous, reaching tens of thousands
or even hundreds of thousands of dollars each year. For instance, the lung
cancer drug Avastin® costs about $100,000 per year; and the cost for
Cerezyme®, used to treat Gaucher disease, can run $300,000 or more per
patient per year. Such high costs put these lifesaving treatments out of
reach for many Americans. The need to act has become more critical as
Congress and the Administration work to reduce health care costs while
increasing access to quality care.
Support for biogenerics has swelled over the past three years: more than 70
corporations, labor unions and consumer organizations—including Fortune 500
companies, the AFL-CIO and Consumer Union—now a
re
advocating that Congress grant FDA the authority and flexibility to put in
place a safe and workable biogeneric approval process. Dozens of governors
and state legislatures also are calling on Congress to pass legislation as
soon as possible that would create a biogeneric market
Europe’s generic medicines companies possess the scientific knowledge and technical experience to produce safe and effective biosimilar pharmaceuticals, which are medicines derived from biotechnology.
And the legislative framework exists in Europe for the European Medicines Agency (EMEA) to evaluate the quality, safety and efficacy of these new biological medicines. Indeed, since 2006 the European Commission has authorized several biosimilar medicines in Europe, declaring that each of them:
“has been compared to and matches the reference medicine [...] in terms of quality (how it is made), safety (for example the side effects that can occur when receiving treatment are similar), and effectiveness.”
Europe’s healthcare systems are eager for the cost relief and the increased patient access to the life enhancing treatments that biosimilar products will bring. ( European Generics Medicines Association. 2009)